128 related articles for article (PubMed ID: 3092390)
1. Increase in plasma concentration of plasminogen activator inhibitor, fibrinogen, von Willebrand factor, factor VIII:C and in erythrocyte sedimentation rate with age.
Aillaud MF; Pignol F; Alessi MC; Harle JR; Escande M; Mongin M; Juhan-Vague I
Thromb Haemost; 1986 Jun; 55(3):330-2. PubMed ID: 3092390
[TBL] [Abstract][Full Text] [Related]
2. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
3. Renal and hepatic handling of endogenous tissue-type plasminogen activator (t-PA) and its inhibitor in man.
Brommer EJ; Derkx FH; Schalekamp MA; Dooijewaard G; vd Klaauw MM
Thromb Haemost; 1988 Jun; 59(3):404-11. PubMed ID: 3142078
[TBL] [Abstract][Full Text] [Related]
4. Plasma levels of von Willebrand factor and plasminogen activator in patients with arterial thromboembolism--with special reference to their correlation to the increased catabolism of both fibrinogen and platelets.
Matsumoto M; Uchiyama T; Kobayashi N; Maekawa T
Nihon Ketsueki Gakkai Zasshi; 1989 Sep; 52(6):1105-14. PubMed ID: 2588960
[TBL] [Abstract][Full Text] [Related]
5. Local and systemic effects of intra-arterial desmopressin in healthy volunteers and patients with type 3 von Willebrand disease. Role of interleukin-6.
Newby DE; Stewart A; Witherow FN; Grieve S; Dawson P; Fox KA; Webb DJ; Ludlam CA
Thromb Haemost; 2000 Aug; 84(2):195-203. PubMed ID: 10959689
[TBL] [Abstract][Full Text] [Related]
6. Acquired von Willebrand's syndrome associated with decrease of plasminogen activator and its inhibitor during hypothyroidism.
Levesque H; Borg JY; Cailleux N; Vasse M; Daliphard S; Gancel A; Monconduit M; Courtois H
Eur J Med; 1993 May; 2(5):287-8. PubMed ID: 8252160
[TBL] [Abstract][Full Text] [Related]
7. Increased PA-inhibitor levels in the postoperative period--no cause-effect relation with increased cortisol.
Aillaud MF; Juhan-Vague I; Alessi MC; Marecal M; Vinson MF; Arnaud C; Vague P; Collen D
Thromb Haemost; 1985 Aug; 54(2):466-8. PubMed ID: 2417352
[TBL] [Abstract][Full Text] [Related]
8. von Willebrand factor antigen, tissue-type plasminogen activator antigen, and risk of death in human immunodeficiency virus 1-related clinical disease: independent prognostic relevance of tissue-type plasminogen activator.
Schved JF; Gris JC; Arnaud A; Martinez P; Sanchez N; Wautier JL; Sarlat C
J Lab Clin Med; 1992 Sep; 120(3):411-9. PubMed ID: 1517688
[TBL] [Abstract][Full Text] [Related]
9. Fibrinolysis and spinal injury. Relationship to post-traumatic deep vein thrombosis.
Petäjä J; Myllynen P; Rokkanen P; Nokelainen M
Acta Chir Scand; 1989; 155(4-5):241-6. PubMed ID: 2508383
[TBL] [Abstract][Full Text] [Related]
10. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1).
Kluft C; Jie AF; Rijken DC; Verheijen JH
Thromb Haemost; 1988 Apr; 59(2):329-32. PubMed ID: 3133814
[TBL] [Abstract][Full Text] [Related]
11. [Thrombomodulin, von Willebrand factor and tissue plasminogen activator in the blood plasma of obese women and men].
Rość D; Drewniak W; Kinasz-Rózycka I; Kulwas A; Michalski A
Pol Merkur Lekarski; 2003 Dec; 15(90):518-20. PubMed ID: 15058251
[TBL] [Abstract][Full Text] [Related]
12. [Anti-activator inhibitors of plasminogen].
Juhan-Vague I; Alessi MC; Aillaud MF
Ann Biol Clin (Paris); 1987; 45(2):202-6. PubMed ID: 3113299
[TBL] [Abstract][Full Text] [Related]
13. [Thrombotic, fibrinolytic and proliferative activities of pulmonary vascular bed in secondary pulmonary hypertension].
Ergün K; Balbay Y; Cihan G; Aras D; Cağli K; Ayaz S; Bilgiç F; Balbay OA; Saşmaz H; Korkmaz S
Anadolu Kardiyol Derg; 2005 Jun; 5(2):95-100. PubMed ID: 15939682
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor activity in bacterial infection.
Páramo JA; Fernández Diaz FJ; Rocha E
Thromb Haemost; 1988 Jun; 59(3):451-4. PubMed ID: 3142082
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolytic and haemostatic responses to desamino-D-arginine vasopressin (DDAVP) administered by intravenous and subcutaneous routes in healthy subjects.
MacGregor IR; Roberts EM; Prowse CV; Broomhead AF; Ozolins M; Litka P
Thromb Haemost; 1988 Feb; 59(1):34-9. PubMed ID: 3129807
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator inhibitor-1 is the primary inhibitor of tissue-type plasminogen activator in pregnancy plasma.
Jørgensen M; Philips M; Thorsen S; Selmer J; Zeuthen J
Thromb Haemost; 1987 Oct; 58(3):872-8. PubMed ID: 3124286
[TBL] [Abstract][Full Text] [Related]
17. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
18. A sensitive assay, specific for endothelial cell type plasminogen activator inhibitor in blood plasma.
Sprengers ED
Thromb Haemost; 1986 Feb; 55(1):74-7. PubMed ID: 3085268
[TBL] [Abstract][Full Text] [Related]
19. Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease.
Bykowska K; Letowska M; Sabliński J; Binder BR; Kopeć M; Lopaciuk S
Acta Haematol Pol; 1994; 25(3):261-8. PubMed ID: 7992599
[TBL] [Abstract][Full Text] [Related]
20. 1-Desamino-8-D-arginine vasopressin (DDAVP) in patients with congenital nephrogenic diabetes insipidus.
Brink HS; Derkx FH; Boomsma F; Brommer EJ; Schalekamp MA
Neth J Med; 1993 Aug; 43(1-2):5-12. PubMed ID: 8232694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
